Asabys portfolio company Agomab Therapeutics completes Nasdaq IPO

Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need, today announced the pricing of its initial public offering raising approximately $200 million in gross proceeds.

Asabys is an investor in Agomab since 2021, when Agomab acquired Origo Biopharma, an Asabys’ portfolio company based in Galicia (Parque Empresarial de Touro). Origo was founded in 2017 by Julio Castro and GalChimia and seeded by Asabys and XesGalicia in 2020. Since Agomab’s acquisition, Asabys continued to support the company through multiple financing rounds, alongside leading global investors such as Pfizer, Fidelity, Sanofi, KKR and EQT, among others.

Notably, Agomab’s assets currently in clinical development originate from Origo Biopharma, validating Asabys’ original investment thesis and its strategy focused on the early support of companies built on differentiated science with transformative potential.

“We are extremely proud to see Agomab reach this important milestone,” said Clara Campàs, Managing Partner of Asabys. “This IPO marks a significant milestone in a journey that began with the creation of Origo Biopharma and reflects our long-term commitment to building companies from the earliest stages around breakthrough science.  We congratulate the Agomab team and look forward to their continued success as a public company.”